KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Cash: 2009-2025

Historic Change in Cash for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $136.2 million.

  • Jazz Pharmaceuticals' Change in Cash fell 84.21% to $136.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$892.1 million, marking a year-over-year decrease of 201.09%. This contributed to the annual value of $906.6 million for FY2024, which is 45.09% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Change in Cash of $136.2 million as of Q3 2025, which was up 120.26% from -$672.1 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Change in Cash high stood at $1.0 billion for Q1 2021, and its period low was -$1.2 billion during Q2 2021.
  • Moreover, its 3-year median value for Change in Cash was $114.4 million (2023), whereas its average is $40.4 million.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Change in Cash showed a top increase of 1,518.11% in 2021 and a maximum decrease of 1,527.71% in 2021.
  • Jazz Pharmaceuticals' Change in Cash (Quarterly) stood at -$80.3 million in 2021, then skyrocketed by 152.44% to $42.1 million in 2022, then surged by 305.04% to $170.6 million in 2023, then grew by 14.13% to $194.7 million in 2024, then tumbled by 84.21% to $136.2 million in 2025.
  • Its Change in Cash stands at $136.2 million for Q3 2025, versus -$672.1 million for Q2 2025 and -$550.9 million for Q1 2025.